Welcome to the UPF Digital Repository

A Pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs Project.

Show simple item record

dc.contributor.author Bioque, Miquel
dc.contributor.author Llerena, Adrián
dc.contributor.author Cabrera, Bibiana
dc.contributor.author Mezquida, Gisela
dc.contributor.author Lobo, Antonio
dc.contributor.author González-Pinto, Ana
dc.contributor.author Díaz-Caneja, Covadonga M.
dc.contributor.author Corripio, Iluminada
dc.contributor.author Aguilar, Eduardo J.
dc.contributor.author Bulbena Vilarrasa, Antonio
dc.contributor.author Castro-Fornieles, Josefina
dc.contributor.author Vieta, Eduard
dc.contributor.author Lafuente, Amàlia
dc.contributor.author Mas, Sergi
dc.contributor.author Parellada, Mara
dc.contributor.author Saiz-Ruiz, Jerónimo
dc.contributor.author Cuesta, Manuel J.
dc.contributor.author Bernardo, Miquel
dc.contributor.author PEPs GROUP
dc.date.accessioned 2016-05-11T10:50:22Z
dc.date.available 2016-05-11T10:50:22Z
dc.date.issued 2016
dc.identifier.citation Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A. et al. A pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016 Mar 31;19(4). pii: pyv121. doi: 10.1093/ijnp/pyv121
dc.identifier.issn 1461-1457
dc.identifier.uri http://hdl.handle.net/10230/26265
dc.description.abstract BACKGROUND: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. METHODS: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. RESULTS: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). CONCLUSIONS: These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
dc.description.sponsorship This study was supported by the Ministerio de Economía y Competitividad (Ref. ISCIII 2009–2011: PI 080208). Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, European Union, una manera de hacer Europa, by the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014SGR441), and by Centro de Investigación Biomédica en Red de salud Mental (CIBERSAM). This work was developed (in part) at the Centro Esther Koplowitz (IDIBAPs, Barcelona).
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartof The International Journal of Neuropsychopharmacology. 2016 Mar 31;19(4): pyv121
dc.rights © The Author 2015. Published by Oxford University Press on behalf of CINP. International Journal of Neuropsychopharmacology, (2016) 19(4): 1–10 doi:10.1093/ijnp/pyv121 Advance Access Publication October 27, 2015 Research Article. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons. org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.other Psicosi
dc.subject.other Esquizofrènia -- Tractament
dc.subject.other Psicofàrmacs
dc.title A Pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs Project.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1093/ijnp/pyv121
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking